Retatrutide in 2026: 30% Weight Loss Results, Early Access Requests, and When the "Triple G" Could Arrive

Retatrutide is an injectable medication from Eli Lilly that activates three different hormone receptors at once: GLP-1, GIP, and glucagon — which is why you will see it called a "triple G" or triple agonist. For comparison, semaglutide (the active ingredient in Wegovy and Ozempic) targets GLP-1 alone, and tirzepatide (Zepbound and Mounjaro) targets GLP-1 plus GIP.

The addition of the glucagon receptor is what researchers believe pushes results further: alongside appetite suppression, glucagon receptor activity is thought to increase energy expenditure. As Dr. Daniel Drucker of the University of Toronto told Scientific American, "This has always been the GLP-1 medicine that we have viewed as the most potent."

Like current GLP-1 medications, retatrutide is taken as a weekly injection and titrated up gradually from a low starting dose.

Lilly's Phase 3 program for retatrutide is called TRIUMPH, and three of its major readouts landed in 2026:

TRIUMPH-1 enrolled adults classified as overweight or obese without diabetes. At the highest dose (12 mg weekly), participants lost an average of 28.3% of their body weight over 80 weeks — roughly 70 pounds from an average starting weight of about 248 pounds. Participants with a higher starting BMI who stayed on treatment for two years lost up to about 30% of their body weight, results Scientific American noted are comparable to what bariatric surgery typically achieves.

TRIUMPH-2, in people with obesity and type 2 diabetes, showed an average of 21% body weight loss after 80 weeks — a strong result for a population that historically loses less weight on these medications.

TRIUMPH-3, in people with obesity and established cardiovascular disease, showed roughly 23% average weight loss at the highest doses, according to BioPharma Dive.

No medication available today has published numbers like these. For context, that puts retatrutide meaningfully ahead of the results semaglutide and tirzepatide showed in their own pivotal trials — though head-to-head comparisons will matter more once retatrutide is approved and studied directly against them.

Short answer: almost certainly not yet — and you should be skeptical of anyone selling "retatrutide" online today.

In August 2026, after months of physician requests and one widely reported compassionate-use case, Lilly confirmed a formal expanded access program. Per AJMC and Becker's, the program is deliberately narrow: it is intended for a limited number of adults who meet specific medical criteria — generally severe, treatment-refractory obesity with serious complications — and who cannot enroll in a clinical trial. Requests must come from a healthcare provider and are reviewed by Lilly case by case.

For the vast majority of patients, that means retatrutide remains out of reach until FDA approval. Importantly, retatrutide is not eligible for legitimate pharmacy compounding — it is an unapproved investigational drug — so websites offering "retatrutide" for sale are selling unregulated research chemicals, not medicine. That is a real safety risk, not a shortcut.

Retatrutide's side effect profile looks broadly similar to existing GLP-1 medications, concentrated in the digestive system. In TRIUMPH-1, roughly a third of participants reported nausea or diarrhea, about a quarter reported constipation, and 10–25% experienced vomiting depending on dose. These effects were most common during dose increases — the same pattern patients see with semaglutide and tirzepatide today, and one reason anti-nausea support is often prescribed alongside GLP-1 therapy.

One open question: in TRIUMPH-3, there were 27 major cardiovascular events in the treatment group versus 23 with placebo. That difference is small and not conclusive, but it means retatrutide has not yet demonstrated the cardiovascular benefit that helped make semaglutide and tirzepatide standards of care, and the FDA will be looking closely at that data.

As with any weight loss medication, retatrutide will not be right for everyone — personal and family history (including thyroid cancer and pancreatitis history), current medications, and other conditions all factor into whether a GLP-1 class drug is appropriate, which is why screening with a licensed provider matters.

Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027 — a slight delay from its original end-of-2026 target, to complete manufacturing and quality-control data, per BioPharma Dive. Under a standard review timeline, that points to a realistic launch window in late 2027 or 2028. Pricing has not been announced.

The practical takeaway: retatrutide is real and the data is remarkable, but it is a 2027–2028 story. If your health would benefit from losing weight now, waiting a year or more for a drug that may or may not fit your situation is rarely the right plan — an average patient starting tirzepatide or semaglutide today will have made most of their progress before retatrutide ever reaches pharmacies.

Proven options are available today. JoeyMed's weight loss program connects you with a licensed provider who reviews your health history, screens for contraindications, and — if appropriate — prescribes treatment shipped directly to you, including high-dose tirzepatide (Tirz HD) for patients who need the strongest currently available option, with anti-nausea support available to make titration easier.

Starting now does not close the door on retatrutide later: if it is approved and your provider believes it is a better fit, switching medications is a routine part of medically supervised weight care. The decision that matters is made with a licensed provider, based on your health — not on headlines. Take the first step at joeymed.com/weight-loss.